Abstract
Background: Allograft coronary artery disease (ACAD) is a common cause of morbidity and mortality post-orthotopic heart transplantation (OHT). ACAD progression may be reduced by modifying cardiovascular risk factors, such as hyperlipidemia and hypertension. We sought to evaluate the management of hyperlipidemia and hypertension among OHT recipients followed in an outpatient cardiac transplant clinic. Objective: The primary objective was to assess the proportion of OHT patients achieving both the recommended LDL target of <2.0 mmol/L and BP targets of <140/90 mmHg (or <130/80 mmHg for diabetics) in an outpatient cardiac transplant clinic. Methods: A cross-sectional retrospective analysis of the medical records of all adult OHT recipients actively followed in our outpatient cardiac transplant between January-March 2009. Results: Of the 193 patients included, both the low-density lipoprotein (LDL) cholesterol and blood pressure (BP) targets were achieved in 111 (57.5%) patients. The LDL target alone was achieved by 140 (72.5%) patients and the BP target alone by 153 (79.3%) patients. Statins were prescribed in 183 (94.8%) patients with a mean LDL of 1.81 mmol/L (±0.55). Angiotensin converting enzyme-inhibitors [ACE-I] (or angiotensin receptor blockers [ARB]) were prescribed in 154 (79.8%) patients, diltiazem in 101 (52.3%) patients, and both in 85 (44.0%) patients, with a mean BP of 124.2/77.8 mmHg (±13.6/8.2). Adverse reactions related to statins, ACE-inhibitors or diltiazem were uncommon and rarely resulted in drug discontinuation. Conclusions: Guideline recommended that LDL and BP targets are achievable in a significant proportion of OHT recipients. The high utilization rates of statins for dyslipidemia and ACE-I (or ARB) and diltiazem for BP were consistent with guideline recommendations for the prevention of ACAD. Despite concerns regarding the potential for pharmacokinetic drug interactions in OHT patients, the reported rates of any drug intolerance to these medications were low in our population.
Highlights
Heart transplantation is a life-saving medical intervention indicated for highly selected patients with end-stage heart disease;
Information was collected between January to March 2009 from the charts by a single investigator and included: 1) demographic data; 2) most recent fasting lipid profile; 3) blood pressure (BP) readings taken during the last three clinic visits; 4) description of statins, Angiotensin-converting enzyme-inhibitors (ACE-Is), and diltiazem therapies; 5) documented intolerances or adverse effects associated with statins, ACE-Is, and diltiazem
Allograft coronary artery disease (ACAD) was diagnosed by coronary angiography with or without myocardial scintigraphy in 43 (22.3%) patients
Summary
Heart transplantation is a life-saving medical intervention indicated for highly selected patients with end-stage heart disease;
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have